Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cephalon has been given the green light by the FDA to market a new sugar-free formulation of Actiq, its breakthrough cancer pain reliever.
Subscribe to our email newsletter
Actiq is the first medication approved for the management of breakthrough cancer pain in patients with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
This sugar-free formulation, which is bioequivalent to the currently available product, is to be marketed for the same indication as Actiq using the same name.
“With this approval, we will move forward with our plans to launch the sugar-free formulation of Actiq in the first half of 2006,” said Dr Paul Blake, executive vice president, worldwide medical & regulatory operations. “We are pleased that we are able to offer one more treatment option to cancer patients with breakthrough pain.”
Actiq contains a strong opioid painkiller called fentanyl that is used to treat breakthrough cancer pain in patients with malignancies who are taking and who are tolerant to around-the-clock opioid medication.